Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gefitinib in Resected NSCLC (BR.19)
NCT00049543Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2002
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Sep 2002; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00049543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049543.